Antimicrobial Nanocoating

抗菌纳米涂层

基本信息

批准号：
7276505
负责人：
R. Giles Dillingham
金额：
$ 39.47万
依托单位：
BRIGHTON TECHNOLOGIES GROUP, INC.
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-04-01 至 2009-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7276505
关键词：
Adhesions Antibiotics Bacteria Biocompatible Catheters Ceramics Cessation of life Characteristics Chemicals Communicable Diseases Communities Complex Condition Corrosion Country Culture Media Dental Dental Instruments Deposition Depth Development Devices Drainage procedure Electrons Elevator Engineering Environment Evaluation Excision Failure Film Free Radicals Friction Gases Goals Government Growth Hand Health Care Costs Health care facility Healthcare Healthcare Industry Hemodialysis Hydrophobicity Implant In Vitro Incidence Indwelling Catheter Infection Invasive Ions Knowledge Laboratories Life Manufacturer Name Measures Mechanical Ventilators Mechanics Medical Medical Device Metals Microbial Biofilms Minerals Morphology Nanostructures Nosocomial Infections Operative Surgical Procedures Organism Patients Performance Persons Phase Plasma Plastics Pliability Plumbing Polymers Predisposition Procedures Process Productivity Property Prosthesis Purpose Quality of life Range Reporting Resistance Resources Shapes Silver Small Business Funding Mechanisms Small Business Innovation Research Grant Stents Sterility Sterilization for infection control Structure Surface Surgical Instruments Techniques Technology Testing Thick Time Tissues Translating Urease Virulent Work antimicrobial base biomaterial compatibility clinically significant cold temperature cost design evaluation/testing hydrophilicity improved in vivo instrument interest microorganism nanocoating nanostructured novel packaging material prevent programs prototype submicron transmission process urinary urologic vapor

项目摘要

DESCRIPTION (provided by applicant): Nosocomial (hospital acquired) infections represent one of the most severe problems facing the health care industry. Of the approximately two million hospital acquired infections reported annually in this country, about half are associated with catheters, ureteral stents, central lines and other percutaneous devices that provide a support surface for organisms to track into deeper tissue. A typical infection can cost as much as $47,000 per patient to treat. Although invasive medical devices such as stents and catheters are pre-sterilized and inserted or implanted under the most sterile conditions available; biofilm growth, encrustation, and subsequent infection are the most common mode of failure. Coatings that could render these devices inherently resistant to biofilm formation and encrustation could significantly reduce the incidence of infections and unnecessary illness, allow better use of health care resources, reduce healthcare costs, and save lives. Encrustation results from mineral incorporation into biofilms on device surfaces. These deposits inhibit drainage; are virulent bacterial reservoirs; and increase susceptibility of the local tissues to infection. Antibiotic strategies have proven to be of little value in preventing biofilm formation and encrustation of stents and catheters. One technique for producing antimicrobial surfaces is to apply a coating which is capable of releasing metal ions when exposed to moisture. Antimicrobial silver ions are particularly useful for in vivo use due to the fact that they are not substantially absorbed into the body. In Phase I, Brighton Technologies Group developed and characterized a novel antimicrobial nanocoating (AMNC) based on gas-phase deposition of a silver salt-containing polymer that effectively inhibits biofilm formation for a wide range of microorganisms. Phase II will extend these results to create an antimicrobial surface that will inhibit biofilm formation and encrustation on medical devices such as stents and indwelling catheters through: 1. Developing techniques for depositing these films on urinary devices such as ureteral stents, Foley catheters, and ureteral catheters. 2. Evaluating important AMNC characteristics such as hydrophobicity/hydrophilicity, coefficient of friction, adhesion and wear resistance. 3. Developing predictive knowledge of activity and effective lifetime of AMNC's as a function of structure and composition. 4. Initiating in vivo performance and biocompatibility evaluations. Approximately two million hospital-acquired infections are reported annually in the USA, 90,000 of which result in death. Reducing the spread of infectious diseases within healthcare facilities, and in the general community would ultimately translate to saving lives, increasing productivity, and improving the quality of life for millions. Brighton Technologies Group, Inc.'s Antimicrobial Nanocoating is designed to render medical device and hand-contact surfaces self-sterilizing to eliminate some the most common conduits for infection transmission.

描述（由申请人提供）：院内（医院获得性）感染是医疗保健行业面临的最严重的问题之一。在该国每年报告的约 200 万例医院获得性感染中，约一半与导管、输尿管支架、中心导管和其他经皮装置有关，这些装置为生物体进入更深的组织提供了支撑表面。每位患者治疗一次典型感染的费用高达 47,000 美元。尽管支架和导管等侵入性医疗器械已预先消毒并在可用的最无菌条件下插入或植入；生物膜生长、结壳和随后的感染是最常见的失败模式。可以使这些设备固有地抵抗生物膜形成和结壳的涂层可以显着降低感染和不必要的疾病的发生率，从而更好地利用医疗保健资源，降低医疗保健成本并挽救生命。结壳是由于矿物质掺入设备表面的生物膜中造成的。这些沉积物会阻碍排水；是有毒细菌的储存库；并增加局部组织对感染的敏感性。事实证明，抗生素策略对于防止生物膜形成以及支架和导管结壳没有什么价值。生产抗菌表面的一种技术是施加一种在暴露于湿气时能够释放金属离子的涂层。抗菌银离子对于体内使用特别有用，因为它们基本上不会被体内吸收。在第一阶段，布莱顿技术集团开发并表征了一种基于含银盐聚合物气相沉积的新型抗菌纳米涂层（AMNC），可有效抑制多种微生物的生物膜形成。第二阶段将扩展这些结果，以创建抗菌表面，通过以下方式抑制医疗器械（如支架和留置导管）上的生物膜形成和结壳： 1. 开发将这些薄膜沉积在输尿管支架、Foley 导管和输尿管等泌尿器械上的技术导管。 2. 评估重要的AMNC特性，例如疏水性/亲水性、摩擦系数、附着力和耐磨性。 3. 开发 AMNC 的活性和有效寿命作为结构和组成的函数的预测知识。 4.启动体内性能和生物相容性评估。美国每年报告约 200 万例医院获得性感染，其中 90,000 例导致死亡。减少医疗机构内和一般社区内传染病的传播最终将转化为拯救生命、提高生产力并改善数百万人的生活质量。 Brighton Technologies Group, Inc. 的抗菌纳米涂层旨在使医疗设备和手接触表面实现自我消毒，以消除一些最常见的感染传播途径。